Moffitt Cancer Center· @MoffittNews · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Happening now at #AACR26 Clinical Trials Plenary: Jonathan Riess, MD (
@riess_md
@UCD_Cancer
) shares preliminary safety and clinical activity of zoldonrasib (RMC-9805) forKRAS G12D non-small cell lung cancer.
Key takeaways:
Zoldonrasib (RMC-9805) is an oral, potent,
Heat 14 · 10 likes · 1 reply · 3 reposts
Source: Moffitt Cancer Center · x.com